

Advanced Vessel- and Cell-Size MRI to Assess Chemo-Radiation Treatment Response in Pediatric Ependymoma Models

JS Song, JL Steiner, D Niemann, AM Griesinger, AM Pierce, MS Brown, NK Foreman, NJ Serkova
Department of Radiology, Anschutz Medical Campus

BACKGROUND

- Ependymoma (EPN) is an aggressive pediatric brain tumor
- After radiation therapy and surgery, EPN recurs in 23-66% of patients. Benefits of chemotherapy are not well defined.
- EPN is characterized by high tumor cellularity, cytological anaplasia, high mitotic index, tumor necrosis, and inflammatory cells such as M2-type myeloid cells.

OBJECTIVE

To develop and optimize an advanced mpMRI protocol to characterize the phenotype and chemo-radiation treatment (CRT) response in an orthotopic mouse of patient-derived xenografts (PDX) of pediatric EPN.


METHODS

Mouse Models:

- Female severe immunodeficient mice (n=22)
- CRT group (10 Gy radiation plus 30 mg/kg 3-fluorouracil) (n=6)

MRI protocol:

- High resolution T2w turboRARE (sagittal and axial) for tumor volume
- Diffusion weighted imaging (DWI) for tumor necrosis, edema, and selective size imaging
- Quantitative T2maps (qT2) (before and 24hr after ferumoxytol injection) and vessel size imaging (VSI) modeling



Analysis:

Analysis performed in ParaVision NEO Software and in house MATLAB simulations.


RESULTS

BASELINE

- All EPN PDX were inoculated in the correct location: cerebellum
- Median Tumor Volume: $21 \pm 12 \text{ mm}^3$
- Increased Blood Vessel Densities: $Q=0.54 \pm 0.12$
- ADC values low at $0.67 \times 10^{-3} \text{ mm}^2/\text{s}$



EARLY RESPONSE TO TREATMENT

- Appreciated as early as 2 days after CRT
- Decreased blood vessel density
- Increased presence of inflammatory macrophages and microglial cells



LATE RESPONSE TO TREATMENT

- Appreciated 2 weeks after CRT
- Decrease in tumor volume: mean 12.24 mm^3 to 4.05 mm^3 ($P < 0.01$)
- Increased ADC values from 0.67 to 1.25 ($P=0.01$)
- Decreased fitted cellularity: 8.5×10^3 to $5.2 \times 10^3 \text{ mm}^{-2}$
- Decreased SSIFT iAUC from 7.1 to 4.2 ($P=0.001$)



CONCLUSIONS & IMPLICATIONS

- Limitation: current focus is on one type of EPN (PFA1 vs PFA2 vs PFB)
- Our PDX models closely mimic histological features, anatomical location and radiological features of the primary tumors
- Early response to CRT: Significant decrease in vasculature and increase in inflammatory cells
- Late response to CRT: Decreased cellularity and cell shrinkage.
- Future studies will further characterize the pathology of these models and investigate the response of PDX EPN to other treatment modalities.

REFERENCES

- Merchant TE. Current Challenges in Childhood Ependymoma: A Focused Review. *J Clin Oncol.* 2017;35: 2364-2369.
- Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. *Radiother Oncol.* 2005;77: 278-285.
- Byer L, Kline CN, Colmean C, Allen IE, Whitaker E, Mueller S. A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. *J Neurooncol.* 2019;144: 445-452.
- Pierce AM, Witt DA, Donson AM, et al. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. *Neuro Oncol.* 2019;21: 1540-1551.

DISCLOSURES

The authors have no financial affiliations or relationships. There was no off-label use of pharmaceuticals in human subjects.

ACKNOWLEDGEMENTS

Dr. Natalie J. Serkova, University of Colorado Cancer Center Grant P30, NIH R01, Shared Instrumentation Grants, St Baldrick Foundation, Michele Plachy-Rubin Brain Tumor Foundation